Peer-Reviewed Publication American Academy of Neurology EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, MONDAY, DECEMBER 23, 2024 MINNEAPOLIS – A drug recently approved to prevent migraine may start working right away, according to a study published in the December 23, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study looked at...
Category: <span>Clinical Practice</span>
Post
100% successful” cancer drug gets landmark FDA approval
By Bronwyn Thompson December 21, 2024 Novel immunotherapy is a potential breakthrough for colorectal cancer suffers Depositphotos View 1 Images Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the Food and Drug Administration granted it Breakthrough Therapy Designation status that, if successful, will expedite its path to market. Dorstarlimab (brand...
Post
Nestle Launches Protein Shots for US Weight-loss Drug Users
Richa Naidu December 18, 2024 46 Added to Email Alert LONDON (Reuters) – Nestle is launching protein shots in the United States which it says help suppress appetite for people looking to shed pounds, the latest effort by the world’s biggest packaged food maker to tap the booming market for weight-loss products. The manufacturer of...
Post
How AI Is Revolutionizing Personalized Health Plans
Posted Today Health, fitness. Image credit: Pexels, free license AI is reshaping how we approach health. It evaluates our unique dietary needs and daily habits, then translates them into actionable plans. Personalized nutrition advice once required extensive consultations or costly services. Today, advanced algorithms streamline that process, making customized guidance more accessible. From recommending nutrient-rich meals...
Post
FDA approves weight loss drug Zepbound to treat obstructive sleep apnea
December 21, 20241:06 PM ET Juliana Kim The Food and Drug Administration has authorized the use of Zepbound for adults with obesity and moderate to severe obstructive sleep apnea. Getty Images/iStockphoto The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea. The Food and Drug Administration on Friday authorized the...
Post
Medicare reveals results of drug price negotiations
Under the Inflation Reduction Act, the U.S. government has for the first time been able to directly negotiate the prices of select drugs within Medicare. Published Aug. 15, 2024 Ned PagliaruloLead Editor In this photo illustration, Farxiga is made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. Scott...
Post
New clinical practice guideline on the process for diagnosing Alzheimer’s disease or a related form of cognitive impairment or dementia
First comprehensive guideline applicable to primary and specialty careReports and Proceedings Alzheimer’s Association Key Takeaways CHICAGO, BOSTON & SUN CITY/PHOENIX, Dec. 23, 2024 — We have entered a new era of improved and emerging biologically-based diagnostic biomarkers for Alzheimer’s disease (AD) and AD-related neurodegenerative disorders (ADRD) that are rapidly impacting evaluation and care paradigms in every...
Post
Should Patients With Thyroid Issues Take GLP-1s? It Depends
Alicia Gallegos December 19, 2024 0140 Added to Email Alert Clinicians frequently reach out to Catherine Varney, DO, asking if it’s safe to prescribe glucagon-like peptide 1 receptor agonists (GLP-1 RAs) to patients with thyroid disorders, such as hypothyroidism, goiter, hyperthyroidism, and nodules. The concerns often stem from prior animal studies that revealed a link between the...
Post
Most Older Adults With HIV Miss Bone Density Scans
Heidi Splete Nearly 90% of people older than 50 years living with HIV have not undergone bone mineral density testing, based on data from approximately 12,000 individuals. Factors including chronic inflammation, immune dysfunction, and side effects from antiretroviral therapy may contribute to accelerated aging in people with HIV, wrote Veronica J. Brady, PhD, of the...
Post
FDA expands approval of Vtama to include atopic dermatitis
by Lori Solomon The U.S. Food and Drug Administration has approved Organon’s Vtama (tapinarof) 1% cream for an additional indication — the topical treatment of atopic dermatitis in adult and pediatric patients aged 2 years and older. ADVERTISING The cream, an aryl hydrocarbon receptor agonist, was previously approved as a topical, nonsteroidal treatment for plaque psoriasis....